Global Bispecific Antibodies Market Companies
- Aspen Holdings
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- GlaxoSmithKline plc.
- Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
- Pfizer, Inc
- Portola Pharmaceuticals, Inc.
- Sanofi S.A.
Recent News:
- In September 2023, Ono Pharmaceutical Co., Ltd., announced that it has entered into a drug discovery collaboration agreement with Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, to discover and develop innovative antibody drugs in the oncology field. Under the terms of the agreement, Adimab will discover novel therapeutic antibodies against multiple targets selected by Ono and generate bispecific antibody product candidates. Ono will evaluate and develop such candidates at the pre-clinical and clinical stages.
- In August 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TALVEY (talquetamab-tgvs), a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
- In July 2022, Janssen Pharmaceutical announced that it had received conditional marketing authorization for Teclistamab in patients with multiple myeloma from the Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). Europe. Additionally, the company has submitted a Biologics License Application (BLA) to the US FDA for approval to market its innovative drugs. The approval was based on favorable results from a late-stage clinical trial that recommended increased survival rates of the drug.